文献速递自身炎症与 IgG4 相关病

JAK抑制剂治疗难治性成人斯蒂尔病与全身型幼年特发性关节炎

JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

这项法国全国调查的回顾性研究纳入9例难治性全身型幼年特发性关节炎或成人斯蒂尔病患者,评估JAK抑制剂(JAKi)的疗效与安全性。结果显示2/9完全缓解、3/9部分缓解、4/9治疗失败,末次访视时糖皮质激素可减量但未能停用,耐受性可接受(无严重不良事件)。作者认为JAKi可能是部分难治性斯蒂尔病患者的治疗选择。

要点

  • 9例难治性斯蒂尔病患者中,2/9完全缓解、3/9部分缓解、4/9治疗失败。
  • 末次访视时糖皮质激素可减量但未停用,JAKi耐受性可接受,无严重不良事件。
  • 作者认为JAKi可能是部分对中高剂量糖皮质激素或生物制剂部分应答患者的治疗选择。

核心结论

  • JAKi可能对部分难治性斯蒂尔病患者是一种治疗选择,尤其是对中剂量或高剂量糖皮质激素或生物制剂部分应答者。

研究设计与样本

  • 本研究为回顾性研究,基于法国医院风湿科、儿科风湿科和内科开展的全国调查,纳入接受JAKi治疗的全身型幼年特发性关节炎或成人斯蒂尔病患者,数据采用标准化问卷收集,并在治疗开始时、第1、3、6个月及随访结束时分析。

主要发现

  • 共纳入9例患者(其中7例成人),所有患者对糖皮质激素或传统合成改善病情抗风湿药或生物制剂应答不足。
  • 巴瑞替尼用于5例,芦可替尼用于2例,托法替布用于2例,乌帕替尼用于1例;除2例外,JAKi均与糖皮质激素联用。
  • 1例JAKi与阿那白滞素及糖皮质激素联用,另1例与甲氨蝶呤、阿那白滞素及糖皮质激素联用。
  • 中位随访16个月(范围1-33个月);9例中2例完全缓解、3例部分缓解、4例治疗失败。
  • 末次访视时糖皮质激素可减量但未能停用;JAKi耐受性可接受,无严重不良事件。

关键数值与推荐

  • 9例中2例完全缓解、3例部分缓解、4例治疗失败。

临床怎么用

  • 作者认为,JAKi可能是部分难治性斯蒂尔病患者的治疗选择,尤其是对中剂量或高剂量糖皮质激素或生物制剂部分应答者。

局限性

  • 本研究为回顾性研究。
  • 共纳入9例患者,样本量小。
  • 中位随访16个月(范围1-33个月),随访时间短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Excessive and inappropriate production of pro-inflammatory cytokines plays a key role in Still's disease. Janus kinase inhibitor (JAKi) agents mainly block pro-inflammatory cytokine pathways, notably IL-6 and IFN. The objective was to assess the efficacy and safety of JAKi agents in difficult-to-treat systemic JIA or adult-onset Still's disease (AOSD). METHODS: This retrospective study was based on a national survey conducted in the departments of rheumatology, paediatric rheumatology and internal medicine of French hospitals regarding systemic JIA and AOSD patients who received JAKi agents. The data were collected with a standardized questionnaire and analysed at different times (treatment initiation, months 1, 3 and 6 and the end of follow-up). RESULTS: Nine patients (seven adults) were included. All patients showed inadequate response to CS or conventional synthetic or biologic DMARDs. Baricitinib was used in five patients, ruxolitinib in two, tofacitinib in two and upadacitinib in one. A JAKi was used combined with CS in all but two patients. A JAKi was associated with anakinra and CS in one patient, and with MTX, anakinra and CS in another. The median (range) follow-up was 16 (1-33) months. Two cases out of nine showed complete remission, 3/9 partial response and 4/9 treatment failure. At the last visit, CS could be decreased but not stopped. Tolerance of the JAKi was acceptable (no severe adverse events). CONCLUSION: JAKi agents may be a therapeutic option for some patients with difficult-to-treat Still's disease, especially those with partial response to medium- or high-dose CS or biologics.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Gillard L, Pouchot J, Cohen-Aubart F, et al. JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Rheumatology (Oxford). 2023. PMID: 35920788. doi:10.1093/rheumatology/keac440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。